Bicara Therapeutics (BCAX) CFO Jennifer Larson Receives Award

What Happened
Jennifer Larson, Chief Financial Officer of Bicara Therapeutics (BCAX), was granted a derivative award of 285,000 shares on August 12, 2026. The Form 4 records the acquisition at $0.00 per share (total reported value $0) and classifies the transaction as an award/grant (code A). This is a compensation-related grant rather than an open-market purchase or sale.

Key Details

• Transaction date: August 12, 2026 (reported on Form 4 filed Aug 14, 2026).
• Transaction type/code: Award/Grant (A) — derivative security.
• Shares/units granted: 285,000; reported price: $0.00; reported total value: $0.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Vesting note (F1): 25% of the shares vest and become exercisable on August 12, 2027; the remainder vests in twelve equal quarterly installments thereafter, subject to continued service.
• Filing timeliness: Filed two days after the transaction date (appears timely under Section 16 reporting rules).
• No indication in the filing that shares were sold or immediately exercised.

Context
This is a time‑based equity award (derivative) intended as compensation. Such grants vest over time and do not represent an immediate purchase or sale; they become meaningful only as they vest and, if applicable, are exercised or settled. Grants are routine for executives and signal compensation alignment but are not direct indicators of immediate insider buying or selling.